SCHEMBL610392

SCHEMBL610392

CN(c1ccc(Cl)cc1)c1ccnc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHKA P35790 7/20 0.69
HPGD P15428 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
CSF1R P07333 1/20 0.43
HRH3 Q9Y5N1 2/20 0.43
EGFR P00533 1/20 0.43
FLT1 P17948 1/20 0.41
KDR P35968 1/20 0.41
DOT1L Q8TEK3 1/20 0.40
NCF1 P14598 1/20 0.40
ALDH1A1 P00352 1/20 0.39
CYP1A2 P05177 1/20 0.39
HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30522270 1.00 CHKA (0.69) CHKAHPGDLMNAMAPTALOX15
SCHEMBL6530619 0.87 CHKA (0.68) CHKAHPGDCSF1RHRH3EGFR
SCHEMBL2219585 0.84 CHKA (0.83) CHKALMNAMAPTALOX15CSF1R
SCHEMBL11136934 0.82 CHKA (1.00) CHKALMNAMAPTCSF1RCYP1A2
SCHEMBL3110770 0.82 CASP1 (0.55) CHKACSF1REGFRKDRALDH1A1
SCHEMBL10062533 0.78 CHKA (0.77) CHKALMNAMAPTALOX15ALDH1A1
SCHEMBL13720967 0.77 CHKA (0.52) CHKAHPGDHRH3EGFRNCF1
SCHEMBL13721231 0.77 CHKA (0.52) CHKAHPGDHRH3EGFRNCF1
SCHEMBL7498608 0.77 CHKA (0.75) CHKALMNAMAPTALOX15CYP1A2
SCHEMBL13450995 0.77 CHKA (0.75) CHKALMNAMAPTALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116178258-B N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-11-21 CN claimed
CN-116178258-A N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-05-30 CN claimed
US-7781458-B2 Derivatives of pyridine and quinoline CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2010-08-24 US claimed
EP-1710236-B1 DERIVATIVES OF PYRIDINE AND QUINOLINE CONSEJO SUPERIOR INVESTIGACION (ES) 2010-03-24 EP claimed
EP-2085386-A2 Pyridinium and quinolinium derivatives as Choline kinase inhibitors Consejo Superior De Investigaciones Científicas (ES) 2009-08-05 EP claimed
US-20070185170-A1 Derivatives of pyridine and quinoline CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-08-09 US claimed
EP-1710236-A1 DERIVATIVES OF PYRIDINE AND QUINOLINE CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2006-10-11 EP claimed
CN-116178258-B N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-11-21 CN disclosed
CN-116178258-A N-methylaniline quinoline compound and synthetic method and application thereof 中国医学科学院北京协和医院 2023-05-30 CN disclosed
WO-2015185780-A1 SYMMETRICAL POLAR INHIBITORS OF CHOLINE KINASE WITH ANTI-TUMOUR ACTIVITY UNIVERSIDAD DE GRANADA (ES) 2015-12-10 WO disclosed
US-20150297576-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TRASLATIONAL CANCER DRUGS PHARMA S L (ES) 2015-10-22 US disclosed
US-20150297576-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TRASLATIONAL CANCER DRUGS PHARMA S L (ES) 2015-10-22 US disclosed
US-20150297576-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TRASLATIONAL CANCER DRUGS PHARMA S L (ES) 2015-10-22 US disclosed
US-20100068302-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER TRASLATIONAL CANCER DRUGS PHARMA, S.L. (ES) 2010-03-18 US disclosed
EP-2085386-A2 Pyridinium and quinolinium derivatives as Choline kinase inhibitors Consejo Superior De Investigaciones Científicas (ES) 2009-08-05 EP disclosed
EP-2085386-A2 Pyridinium and quinolinium derivatives as Choline kinase inhibitors Consejo Superior De Investigaciones Científicas (ES) 2009-08-05 EP disclosed
US-20070185170-A1 Derivatives of pyridine and quinoline CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-08-09 US disclosed
US-20070185170-A1 Derivatives of pyridine and quinoline CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-08-09 US disclosed
US-20070185170-A1 Derivatives of pyridine and quinoline CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2007-08-09 US disclosed
EP-1710236-A1 DERIVATIVES OF PYRIDINE AND QUINOLINE CONSEJO SUPERIOR INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2006-10-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150297576-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER ASAH1, ACER2, ASAH2 CHKA 4/4885HPGD 2035/4885LMNA 2716/4885
US-20070185170-A1 Derivatives of pyridine and quinoline CHKA, CHKB, PHOSPHO1 CHKA 1/4885HPGD 1536/4885LMNA 1938/4885
US-20100068302-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER ASAH1, ACER2, ASAH2 CHKA 4/4885HPGD 2035/4885LMNA 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.